The word cancer elicits dread in nearly everyone. Cancer accounts for considerable mortality and morbidity in both men and women (Kozier, 2004). Certain genes controlling growth and interactions with other normal cells are apparently abnormal in structure or regulation in cancer cells. Humans of all ages develop cancer, and a wide variety of organs are affected. The incidence of many cancers increases as the fourth to sixth power of age, so that as people live longer, many more will develop the disease. Apart from individual suffering, the economic burden to society is immense (Murray, et al, 2000).


Cancer cells are characterized by three properties: (1) diminished or unrestrained control of growth; (2) invasion of local tissues; and (3) spread, or metastasis to other parts of the body. Cells of benign tumors also show diminished control of growth but do not invade local tissue or spread to other parts of the body (Murray, et al, 2000).


            Cancer is caused in all or almost all instances by mutation or by some other abnormal activation of cellular genes that control cell growth and cell mitosis. The abnormal genes are called oncogenes. Cancer tissue competes with normal tissues for nutrients. Because cancer cells continue to proliferate indefinitely, their number multiplying day by day, one can readily understand that the cancer cells soon demand essentially all the nutrition available to the body or to an essential part of the body. As a result, normal tissues gradually suffer nutritive death (Guyton & Hall, 2000).


An abnormal cell mass that develops when controls of the cell cycle and cell division malfunction is called a neoplasm. However, not all neoplasms are cancerous. Benign neoplasms are strictly local affairs. They tend to be surrounded by a capsule, grow slowly, and seldom kill their hosts if they are removed before they compress vital organs. In contrast, malignant (cancerous) neoplasms are nonencapsulated masses that grow more relentlessly and may become killers. Their cells resemble immature cells, and they invade their surroundings rather than pushing them aside, as reflected in the name cancer from the Latin word for “crab.” Malignant cells also tend to spread via the blood to distant parts of the body, where they form new masses. This last capability is called metastasis (Marieb 2004).


Genetic aspects of cancer are probably receiving the greatest current attention among genetic abnormalities. Some cancers are caused by oncogenes, genes which are carried in the genomes of cancer cells and are responsible for producing their malignant properties. These genes are derived by somatic mutation from closely related proto-oncogenes, which are normal genes that control their growth. Over 100 oncogenes have been described (Ganong, 2001).


Obviously, the initiation of mitosis and normal cell division depends on the orderly occurrence of events during what has come to be called the cell cycle. There is intense interesting the biochemical machinery that produces mitosis, in part because of the obvious possibility of its relation to cancer. When DNA is damaged, entry into mitosis is inhibited, giving the cell time to repair the DNA; failure to repair damaged DNA leads to cancer. The cell cycle is regulated by proteins called cyclins and cyclin-dependent protein kinases, which phosphorylate other proteins (Ganong, 2001).


Cell replication involves not only DNA polymerase but a special reverse transcriptinase that synthesizes the short repeats of DNA that characterize the ends (telomeres) of chromosomes. Cells with high telomerase activity, which includes most cancer cells, can in theory keep multiplying indefinitely (Ganong, 2001).


           


Cell Division in normal and cancer cells.


Source: http://www.ch.ic.ac.uk/local/projects/burgoine/origins.txt.html


            The stepwise development of a typical colon cancer is as follows:


 


1


2


3


Cellular changes


Increased cell division


Growth of polyp


Growth of malignant tumor (carcinoma)


DNA changes


Oncogene activated


Tumor-suppressor gene activated


Second tumor-suppressor gene activated


 


The treatment of choice for either type of neoplasm is surgical removal. If surgery is not possible – as in cases where the cancer has spread widely or is inoperable – radiation and drugs (chemotherapy) are used. Chemotherapeutic drugs destroy malignant cells (Kozier, 2004).


 


When chemotherapy or radiotherapy is used in addition to surgery it is known as ‘adjuvant chemotherapy’ or ‘adjuvant radiotherapy’. For example, following surgery you may be given a course of chemotherapy or radiotherapy. This aims to kill any cancer cells which may have spread away from the primary tumor site. Sometimes, adjuvant chemotherapy or radiotherapy is given before surgery to shrink a large tumor so that the operation to remove the tumor is easier for a surgeon to do, and is more likely to be successful.


            Cytotoxic therapy regimens are highly toxic to cells, and can result in a range of acute and chronic adverse effects for persons receiving these treatments (Perry, 1996). A number of these adverse effects are potentially life threatening. The safe and effective delivery of these drugs therefore requires highly complex clinical assessment, technical and problem solving skills.


Surgery, radiotherapy, and chemotherapeutic agents are the major modalities used to treat patients with cancer, though various biologic therapies are beginning to have a significant impact. The basic problem is to make available drugs (natural products or synthetics) that kill cancer cells effectively but are not excessively toxic to normal cells. The table below lists seven major classes of compounds that have been widely used in the treatment of cancer:


Class of Compound


Example


Site of Action


Treatment Use


Alkylating agents


Melphalan


Alkalytes DNA and other molecules


Myeloma


Antimetabolites



  • Purine antagonists


 



  • Pyrimidine antagonists


 



  • Folate antagonists


 


Mercaptopurine


 


 


Fluorouracil


 


 


Methotrexate


 


Converted to a “fraudulent” nucleotide and inhibits purine synthesis


Converted to a “fraudulent” nucleotide and inhibits thymidylate synthetase


Inhibits dihydrofolate reductase


 


Acute myelocytic leukemia


 


Colorectal cancer


 


 


Choriocarcinoma


Antitumor antibiotics


Doxorubicin


Intercalates in DNA and stabilizes the DNA-topoisomerase II complex


Hodgkin’s disease


Other agents


Cisplatin


 


Hydroxyurea


Causes strand breakage in DNA


Inhibits ribonucleotide reductase


Carcinoma of the lung


Chronic myelocytic leukemia


Plant compounds


Vinblastine


Binds tubulin and inhibits microtubule formation


Kaposi’s sarcoma


Sex hormones


Estrogens


Block effects of androgens in prostatic tumors


Cancer of the prostate


Corticosteroids


Prednisone


Inhibits proliferation of lymphocytes


Myeloma


Source: Harper’s Biochemistry, page 806


 


            Insofar as unrestrained cell division is a feature that typifies many malignant tumors, many of these agents are used because they inhibit DNA synthesis. For this reason, they are also likely to damage normal tissues whose cells divide continuously – e.g. bone marrow (Murray, et al, 2000).


Anti-cancer drugs have unpleasant side effects because most target all rapidly dividing cells, including normal ones. The side effects include nausea, vomiting, and loss of hair. X rays also have side effects because, in passing through the body, they kill healthy cells that lie in the path to the cancer cells (Marieb 2004). Life threatening adverse reactions and side effects of the treatment include pulmonary fibrosis and anaphylaxis/anaphylactoid reactions. The most frequent includes fatigue, diarrhea, nausea, vomiting, anemia and neurotoxicity (Deglin & Vallerand, 2004).


            Current cancer treatments – “cut, burn, poison” – are recognized as crude and painful. Promising new methods focus on delivering anticancer drugs precisely to the cancer (via monoclonal antibodies that respond to one type of protein on a cancer cell) and on increasing the immune system’s ability to fend off cancer (Marieb 2004).


In all these, the senior oncology / colorectal specialist nurses is responsible for co-ordinating care following any operations and/or treatment for bowel cancer. A senior oncology nurse is highly qualified, having specialized training in caring for patients who have bowel disease, and has many years of experience in this field. As well as supporting John and his family through his operation and treatment, the senior oncology nurse provides John and his caregivers with clear written and verbal information; and can also examine John and arrange any tests he might need.


The number of patients suffering from cancer has steadily increased in recent years mainly due to an ageing population. Add to this, an increasing number of chemotherapeutic agents and a multitude of regimes, it therefore becomes imperative to educate the nurse on the care of the chemotherapy patient.


Because of all these mentioned, it was only fitting that a study was made to assess the cancer nursing research papers published in the past decade; identify their characteristics in terms of country of origin, participants, settings, diagnostic foci, and methodologic choices; and evaluate their quality as this would significantly help cancer treatments.


A systematic review was carried out of all published papers in the Cumulative Index of Nursing and Allied Health Literature between the years 1994 and 2003, using the keywords “cancer,” “nursing,” and “research.” A total of 619 papers met inclusion criteria and were evaluated by 5 researchers. Almost half the papers were derived from the United States (49.1%), followed by the UK, Sweden, Canada, and Australia.


In more than half of the published papers (52.2%), health professionals (mostly nurses) were the studies’ participants. Also, much of the published research used patients with mixed diagnosis, or patients with breast or hematologic cancers. Two-thirds of the studies were quantitative, whereas most studies were descriptive in nature. The quality of both quantitative and qualitative studies was low, with only a small percentage meeting the highest quality criteria.


Studies reporting funding and those published in journals with an impact factor showed a higher quality score than those not reporting funding or not published in journals with an impact factor.


Concern for global health issues goes with a global perspective in nursing knowledge. As nations become increasingly interdependent, health for all is a worldwide goal, and the framework of health care constrained by national boundaries does not fit nursing (Messias, 2001). A widely recognized advantage of globalization is improved access to information. In nursing, global communication increases through print journals, electronic journals, online educational materials, and international conference proceedings. Worldwide dissemination of nursing information represents a novel opportunity to expand the reach and effect of professional nursing. Accordingly, interest in international collaboration has increased in the published literature in the past decade.


            International collaborations are important because they (a) improve knowledge and understanding of human needs across geographic boundaries, (b) support a global perspective for nursing by fostering worldwide inclusiveness, and (c) expand the cultural and ethical values underpinning goals in nursing. Globalization in knowledge development is linked to international publication in nursing. Knowledge about the international content of nursing journals is a necessary part of understanding the trend toward globalization of nursing knowledge. The systematic study of the international content of highly ranked nursing journals in 2000 was a way to benchmark the status of international publication in nursing (Seers, 2004).


Many issues about globalization have been raised in the nursing literature. Consensus is apparent that the development of international nursing requires a global focus and international collaboration. Leaders question whether Western science can be adapted to a global health framework and whether Western nursing is appropriate for global nursing practice. Nurses realize that Western science does not have answers in all areas of nursing practice (Holt et al., 2000) because knowledge and research development are embedded within cultural contexts (Lutzen, 2000). In a global nursing framework, nurses should emphasize the concept of cultural sensitivity. International comparisons of cultural values are necessary because they help researchers become aware of how different values influence the development of nursing knowledge and practice (Lutzen, 2000). Scholars should be aware of their own knowledge and cultural values, and they should be encouraged to understand alternative ways of thinking (Holt et al., 2000). International collaboration (a) provides alternative modes of thinking for nursing scholars, (b) enables wide-range testing of theories in practice, (c) facilitates scholarly maturity through self-assessment, and (d) leads to advancement of nursing science (Seers, 2004). To investigate the international focus in journals, those journals have to be identified.


            The advancement in biotechnology is also helping to speed up and improve cancer research in many parts around the world. Technology has allowed many medical institutions to do what they are doing today. In cancer research, getting the data and results from DNA sample of patients is important in helping them understand why some people have cancer. In the past, this process was tedious and would take up days, months, and even years before the researcher can get the data and results, let alone the analysis. But with the existence of machines like the DNA sequencer and the microarray technology, cancer research has been sped up and can be done at a higher throughput. For instance, DNA sequencing is now quite a routine procedure in many laboratories and research centers (Ismail, 2003).


Progress in the understanding of genetics, and its role in disease and cancer epidemiology, have scientists encouraged that they are on the brink of major advances in methods and treatments. These include the ability to target cancerous cells without harming healthy tissue as well as better targeted treatments for specific cancers based on understanding of their genetic structure. While the billions of dollars being spent on cancer research by the federal government is significant, it seems that now is the time to aggressively push forward, not cut back (Ernst, 2006). Overall worldwide spending for cancer research is growing. This is good news for the health care consumer, who probably doesn’t care where therapies are developed as long as their treatment is successful.


            New understanding of how cancer cells survive, thrive, and metastasize has enabled researchers to create new targeted therapies for cancer treatments, such as melanoma and Kaposi’s sarcoma, to minimize the harmful systemic effects (therapy on healthy cells. The specific and selective targets of future oncology drugs will require a detailed understanding of cancer cell biology, genetics, immunology, and biotechnology (Capriotti, 2005).


            The search for anti-cancer therapies which target cancer cells specifically and selectively with less toxicity has been a quest in oncology for many years. Conventional chemotherapeutic agents do not target cancer cells selectively, leading to widespread adverse systemic effects. Chemotherapy, radiation therapy, and biological agents all target cells that are in the process of proliferation. Therefore, both cancer cells and mitotically active healthy cells are subject to the cytotoxic effects of these therapies.


            The diagnosis of cancer and other life-threatening diseases can be devastating to patients and their families. While many complex, disease-focused medical procedures are routinely prescribed for patients, often little or no consideration is given to prescribing comfort measures and sustaining optimal quality of life. Nurse educators are on the front lines in promoting the holistic care that is essential for the nurturing of persons with cancer and other serious illnesses (Milone, 2004).


            Among the many challenges faced by individuals affected by life-threatening illnesses are profound changes in social roles and interpersonal relationships. Maintaining employment is difficult, and parenting, socializing with friends, and spiritual well-being are all affected. The whole person suffers by a threat to any one of four dimensions: physical, psychological, social, or spiritual. However, nurses who possess effective communication skills can positively influence rate of recovery, optimize pain control interventions, and better facilitate emotional well-being.


            With regard to the nursing workforce specializing in the care of patients with cancer, little empirically based information is available describing the extent to which the above problems also affect oncology nurses. Because most people who have cancer are older, the aging of the baby boom generation is expected to increase the number of people with cancer substantially, and hence the future demand for oncology nurses. Cancer is the second leading cause of death in the many countries, exceeded only by heart disease. Today, however, reports of shortages of oncology nurses are not uncommon, and because many cancer facilities report difficulty retaining nursing staff, information is needed on the adequacy of the oncology nurse workforce (Mallory, 2001).


            A study confirms long-held suspicions that lung cancer, the leading cancer killer of both men and women, is seriously underreported when compared to other major cancers. In an analysis of 600 randomly selected cancer stories that appeared between August 1999 and July 2000, 61 percent reported on breast cancer, 23 percent on prostate, 17 percent on colorectal cancer and only 9 percent focused on lung cancer outside of tobacco and smoking issues. This is especially significant since more people die each year of lung cancer than the combined deaths from breast, prostate and colorectal cancer.


            Studies on cancer also further demonstrate the overwhelming ability of celebrities to draw attention to cancer issues. Breast, prostate and colorectal cancers generated significant news attention through a number of celebrities who were affected, either directly or indirectly, by the disease. Television host Katie Couric significantly raised awareness of colorectal cancer on her program The Today Show; New York Mayor Rudolph Giuliani’s prostate cancer diagnosis drove coverage to peak levels. Only one celebrity was quoted speaking out for lung cancer, cyclist and cancer survivor Lance Armstrong, who was involved in the Lung Cancer Awareness Campaign in 1999.


            Cancer nurses report a rising workload and concerns about a national shortage of nurses in the speciality, a Senate inquiry has been told. A federal government report had found there was a shortage of oncology and palliative care nurses in every state and territory except the Northern Territory, the Cancer Nurses Society of Australia (CNSA) told the inquiry into cancer services. Recent research into the workloads of cancer nurses found 50% of cancer nurses did not have time to get through their work, and 70% said they were experiencing ‘moderate to high levels of emotional exhaustion’, the society said in its submission.


            The CNSA called for governments to improve cancer nurse staffing models; provide financial support to nurses to pursue further studies; and fund research into innovative models of cancer care involving specialist cancer nurses. A national approach was needed to address the workforce shortages of cancer nurses, particularly improving the available data on cancer nurses in the workforce and developing a national plan to improve staff retention and support strategies (Australian Nursing Journal, 2005).


            As a result of improved diagnosis and treatment, more people are surviving cancer (National Cancer Institute, 2003). Cancer survival, however, can be attended by negative physical and psychological syndromes, including weight gain, lowered aerobic capacity, depression, anxiety and an overall decrease in quality of life. In addition, cancer survivors are at increased risk for developing other chronic conditions such as cardiovascular disease, obesity and diabetes. Reasons for these risks are complex and include genetics, treatment factors, lifestyle factors and a sedentary lifestyle (Grubbs, 2004).


            Research on cancer survivors suggests that weight gain, depression, anxiety and other issues contributing to decreased longevity and quality of life can continue long after the course of treatment. In a study of breast cancer survivors eight years postsurgery, it was also reported that women had persistent symptoms of psychological and somatic disturbance. Most studies on the physical and psychosocial effects of cancer have focused on the period during treatment or within two to three years of diagnosis. Very little is known regarding the longevity of these sequelae, their impact on the aging survivor or the interventions that will improve quality of life (Grubbs, 2004).


            Findings from this study, as well as others, suggest that these health issues may persist beyond the period of chemotherapy and radiation treatments. These studies highlight the longevity of mental and physical changes, depression and decreased quality of life among cancer survivors. The findings emphasize the need for improved systems of care to minimize health disparities, and further research on interventions to improve health outcomes.


            Research evaluation is indeed currently enjoying a favoured position in many countries as research budgets expand but there is also pressure from funders to ensure value for money (Saegusa, 1999). In several European countries, for example, there is a move to more competitive funding both of laboratories and of individual research projects (Goddard, 2000). The ultimate test of the utility of research is that it will give rise to new products and processes or, in the biomedical field, to better health for man and animals. However, the route to these tangible benefits is often lengthy, especially for basic research (Patel et al., 1999), so that proxy indicators are needed to show whether given expenditures have been worthwhile. The main proxy indicator is the esteem in which research is held by other researchers, which can be measured by the counting of citations. However, these suffer from some disadvantages:



  • they are somewhat costly to determine – typically about US per paper;

  • it takes time for them to accumulate, so that fair comparisons can be made – perhaps five years; and

  • comparisons between different fields and sub-fields are difficult because citation norms differ greatly.


In some ways, the analysis of the factors that lead to high quality research is comparable with epidemiology. In this subject, the factors that lead to ill-health are analyzed. The problem in both analyses is that there may be missing factors, some of which are correlated with the ones used for analysis, and which can confound the apparent conclusions. For example, ill-health is positively associated with smoking, a poor diet, lack of exercise and a low-status job (Marmot and Bobak, 2000). But each of these factors is strongly associated with the three others and indeed with yet more factors that can plausibly lead to ill-health, such as low income, low education level, poor housing and living in a polluted area. If public health measures are to be soundly based, it is essential that the individual effects of all these factors, and probably many more, are teased out, so that policies can be targeted on the most important ones.


Similarly, the factors that lead to high quality research may plausibly include:



  • the subject area of the research;

  • whether it is applied or basic (in biomedicine, clinical or basic);

  • whether it is carried out in an industrial or academic setting (in biomedicine, in a hospital or a university);

  • whether the team of authors is large and multi-disciplinary or small;

  • whether there is inter-laboratory collaboration;

  • whether there is international collaboration and, if so, with which country or countries;

  • whether the research has been reviewed by a peer-review committee for funding and, if so, by how many;

  • whether the research has been funded by a particular sector (government, private-non-profit, industry); and

  • the city in which the research has been conducted.


Cancer nursing research is still in a developmental stage, although it has made a considerable contribution to the evidence base of the discipline. A number of issues need to be tackled before we improve our output, such as organizational or workforce issues, infrastructure support, funding, and methodologic challenges.


 


 


 


 


Bibliography


Capriotti, T. (2005). New Oncology Strategy: Molecular Targeting of cancer Cells.


Dermatology Nursing.


Doenges, M. and Moorhouse, A. (2004). Nurse’s Pocket Guide: Diagnoses,


Interventions, and Rationales 9th Edition. F.S. Davis Publishing.


Ernst, S. (2006). What is Cancer Research Worth? Bioscience Technology.


Ganong, W. (2001). Review of Medical Physiology 20th Edition. McGraw-Hill.


Goddard, A. (2000), “Research faces big overhaul”, THES, No.1 September,


pp.4.


Grubbs, R. (2004). Health Disparities in Practice and Research for Aging Women


with Cancer. Journal of Cultural Diversity.


Guyton, A. and Hall, J. (2000). Textbook of Medical Physiology 10th Edition.


Harcourt Asia Pte Ltd.


Holt, J., Barrett, C., Clarke, D., & Monks, R. (2000). The Globalization of Nursing


Knowledge. Nurse Education Today, 20(6), 426-431.


Ismail, I. (2003). Adding Value to Cancer Research. New Straight Times.


Kozier, B. and Erb, G. (2004). Fundamentals of Nursing: Concepts, Process, and


Practice 7th Edition. Pearson Education Inc.


Lutzen, K. (2000). A Global Perspective on Domestic and International Tensions


in Knowledge Development. Journal of Nursing Scholarship, 32, 335-337.


Mallory, G. (2001). State of Oncology Nursing Workforce: Problems and


Implications for Strengthening the Future. Nursing Economics.


Marmot, M., Bobak, M. (2000), “International comparators and poverty and health


in Europe”, British Medical Journal, Vol. 321 pp.1124-8.


Messias, D.K. (2001). Globalization, Nursing, and Health for All. Journal of


Nursing Scholarship, 33, 9-11.


Milone, M.A. (2004). Oncology Nursing Education: Teaching Strategies That


Work. Nursing Education Perspectives.


Molassiotis, A., Gibson, F., Kelly, D., Richardson, A., Dabbour, R.,  Ahmad, A., &


Kearney, N. (2006). A Systematic Review of Worldwide Cancer Nursing Research: 1994 to 2003. Cancer Nursing. 29(6):431-440,.


National Cancer Institute. Retrieved April 10, 2003, from


http://www.nci.nih.gov/cancer_information/cancer_type/breast


Murray, R.K., Granner, D.K., Mayes, P.A. & Rodwell, V.W. (2000). Harper’s


Biochemistry 25th Edition. McGraw-Hill.


No Author. (2005). Cancer Nurses Burn Out. Australian Nursing Journal.


Patel, K., Thomson, A., Tysome, T., Utley, A., Wojtas, O. (1999), Nurturing the


creative, THES, No.3 December, pp.6.


Perry, M.C. (1996). The Chemotherapy Source Book 2nd Edition. Williams and


Wilkins.


Saegusa, A. (1999), “Japanese labs balk at bid to boost external evaluation”,


Nature, Vol. 397 No.6718, pp.378.


Seers, K. (2004). International Content of High Ranking Nursing Journals in the


Year 2000. Journal of Nursing Scholarship.



Credit:ivythesis.typepad.com


0 comments:

Post a Comment

 
Top